North End Cyclery Ltd.


POZEN enter license agreement to develop and commercialize MT 400 POZEN Inc.

MT 400 is usually POZEN’s proprietary mix of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treating migraine. POZEN previously licensed U.S. Related StoriesCalcitonin-gene related peptide antibody inhibition displays migraine prevention promiseCombatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr ChakravarthyMigraines may boost risk of stroke among smokersUnder the conditions of the agreement, Cilag will end up being POZEN’s unique licensee for MT 400 in the certified territory and you will be responsible for the manufacturing, commercialization and development of MT 400.However, in light of the ongoing work of Dr. D’Amore and others, in elucidating feasible systemic and ocular unwanted effects of these drugs, ‘caution must be exercised in identifying patients at increased risk of problems with long-term VEGF blockade, and potential side effects must be detected early in the assessment of patients who’ll require repeated dosages of anti-VEGF agents.’ The analysis is relevant to the drug Avastin also, which was primarily approved for intravenous use as an anti-angiogenic agent in the treatment of cancer, but can be widely used intravitreally for the treating wet AMD due to the similar setting of action and much lower cost.